Skip to main content

Samsara BioCapital — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.8B
Total invested
$105.2M
Avg. check
16
Industries
Biotechnology 22Health Care 16Medical 10Pharmaceutical 8Therapeutics 8Life Science 7+10 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 132
Alpine Immune Sciences
November 2023

Alpine Immune Sciences is an immunotherapy company focused on developing treatments for autoimmune and inflammatory diseases.

Biotechnology · Seattle$150.0M Post-IPO Equity
Arcellx
November 2023

Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.

Biopharma · Redwood City$200.0M Post-IPO Equity
Alamar Biosciences
January 2026

Powering precision proteomics to enable to the earliest detection of disease.

Biotechnology · Fremont$50.0M Convertible Note
Centessa Pharmaceuticals
November 2025

Centessa Pharmaceuticals is a pharmaceutical company that focuses on drug development to address significant medical needs.

Biotechnology · Cambridge$250.0M Post-IPO Equity
Cypherpunk Technologies (formerly Leap Therapeutics)
October 2025

Cypherpunk is a biopharmaceutical company developing antibody therapies for cancer while executing a digital-asset treasury strategy.

Biotechnology · Cambridge$58.9M Post-IPO Equity
Exo Therapeutics
October 2021

Exo Therapeutics is a small molecule drug discovery and development company.

Biotechnology · Cambridge$78.0M Series B
Enara Bio
October 2024

Ervaxx is illuminating the immune interface to develop new cancer therapies.

Biopharma · Oxford$32.5M Series B
Rani Therapeutics
October 2025

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes.

Biotechnology · San Jose$60.3M Post-IPO Equity
Excellergy
October 2025

Excellergy develops immunology-based therapies focused on treating allergic diseases through novel biologic drug candidates.

Biotechnology · Palo Alto$70.0M Series A
Primmune Therapeutics
January 2026

Primmune Therapeutics is a Biotechnology company.

Biotechnology · San Diego$23.3M Series B
EpiBiologics
January 2026

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

Biotechnology · San Mateo$107.0M Series B
Kalaris Therapeutics (formerly AlloVir)
December 2025

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases.

Biotechnology · Houston$50.0M Post Ipo Equity
Link Cell Therapies
December 2025

Link Cell Therapies is a biotechnology company that specializes in cancer cell therapy research and development services.

Biotechnology · San Francisco$60.0M Series A
Contineum Therapeutics
December 2025

Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.

Biotechnology · San Diego$99.2M Post Ipo Equity
Psivant Therapeutics
December 2025

Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services.

Biopharma · Watertown$47.5M Series A
Enlaza Therapeutics
September 2025

Enlaza Therapeutics is a biotechnology research company.

Biopharma · La Jolla$15.0M Series Unknown
Prime Medicine
August 2025

Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.

Biotechnology · Cambridge$5.0M Post Ipo Equity
Abivax
July 2025

Abivax develops medicines that alter the body's natural immune system mechanisms.

Biotechnology · Paris$747.5M Post Ipo Equity
Shenandoah Therapeutics
June 2025

Shenandoah Therapeutics is a biotechnology company.

Health Care · South San Francisco$20.0M Seed
Spyglass Pharma
June 2025

Spyglass Pharma provides medicine for ophthalmic diseases.

Delivery · Aliso Viejo$75.0M Series D
Alpheus Medical
May 2025

Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers.

Biotechnology · Oakdale$52.0M Series B
A2 Biotherapeutics
May 2025

A2 Biotherapeutics develops T cell therapies targeting solid tumors precisely.

Biotechnology · Agoura Hills$300K Grant
Surrozen
March 2025

Surrozen is a biopharmaceutical that focuses on unlocking the body’s regenerative power to treat injury and disease.

Biotechnology · South San Francisco$175.0M Post Ipo Equity
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A

Where Samsara BioCapital invests

Biotechnology22
Health Care16
Medical10
Pharmaceutical8
Therapeutics8
Life Science7

About Samsara BioCapital's portfolio

How many companies has Samsara BioCapital invested in?

Samsara BioCapital has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Samsara BioCapital invest in?

Samsara BioCapital's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 16 different industry categories.

What is Samsara BioCapital's largest investment?

Among tracked funding rounds, Abivax received $747.5M in a Post Ipo Equity round. Samsara BioCapital's total known invested capital is $12.8B.

What is the average investment size for Samsara BioCapital?

Samsara BioCapital's average investment size is $105.2M across its portfolio of 132 companies.

What are Samsara BioCapital's most recent investments?

Recent Samsara BioCapital portfolio additions include Alpine Immune Sciences, Arcellx, Alamar Biosciences, Centessa Pharmaceuticals, Cypherpunk Technologies (formerly Leap Therapeutics). These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →